机理性洞察力对埃索诺菲尔性食管炎:针对病理生理机制的治疗方法
Sara Massironi1,2, Giacomo Mulinacci1,2, Camilla Gallo1,2
1Division of Gastroenterology, Center for Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.
Cells
|October 27, 2023
概括
性食道炎 (EoE) 是由遗传学,过敏原和免疫反应驱动的慢性食道炎症. 了解EoE病原体是开发针对这种复杂疾病的向治疗的关键.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 病理学 病理学 病理学
背景情况:
- 性食道炎 (EoE) 是一种慢性食道炎症状况.
- EoE的发病包括遗传因素,环境触发因素和免疫失调,特别是2型T辅助细胞 (Th2) 细胞因子,如IL-4,IL-5和IL-13.
- 关键的病理特征包括表皮屏障功能障碍,巨细胞激活,氨基酸脱粒和纤维化,导致像狭窄这样的并发症.
研究的目的:
- 阐明异性食道炎 (EoE) 复杂的病原遗传机制.
- 突出遗传倾向,环境触发因素和免疫反应在 EoE 发育中的作用.
- 强调需要更深入的理解来开发新的治疗策略.
主要方法:
- 审查关于EoE病变的现有文献.
- 分析遗传,环境和免疫因素之间的相互作用.
- 检查涉及Th2细胞因子的分子通路及其对食道组织的影响.
主要成果:
- EoE的特点是食道的eosinophilic透,由Th2细胞因子 (IL-4,IL-5,IL-13) 驱动.
- 表皮屏障功能障碍,巨细胞激活和氨基酸脱粒化有助于炎症和组织重塑.
- 慢性炎症可能导致纤维化,狭窄和动力障碍.
结论:
- 目前的EoE治疗方法有限,需要先进的治疗方法.
- 新兴疗法针对关键的炎症途径,包括针对IL-4,IL-5和IL-13的单克隆抗体.
- 对EoE病原体的全面理解对于开发个性化和有效的治疗方法至关重要.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
312
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
312
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
93
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
93
01:21Barrett Esophagus-II: Clinical Manifestations and Management
168
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
168
01:26Peptic Ulcer Disease IV: Management
96
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
96
01:19Antiasthma Drugs: Leukotriene Modifiers
324
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
324
01:20Asthma: Pathogenesis and Management
421
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
421